The capex-meets-IP fact first: a lot of leading-edge process technology is proven in research consortia before any foundry ships it. US11257764B2, granted to imec in early 2022, patents an integrated circuit with a backside power delivery network and backside transistor (CPC H01L 23/5384).
Gloss it once. In a conventional chip, both signal wires and power wires sit above the transistors, competing for space. Backside power delivery moves the power rails to the underside of the wafer, freeing the front side for signal routing and delivering cleaner power. The payoff is density and performance — which is why the leading foundries adopted it as a flagship node feature.
Why a capex desk reads an imec grant: imec is a research consortium, not a manufacturer. Its role is to de-risk expensive process options for the industry. A backside-power patent in its portfolio is a marker that the technique was validated at the research level — the step before any company commits the capital to put it in a high-volume fab.
The period framing matters. This grant predates the volume foundry rollout of backside power. Reading it now shows the research-to-production pipeline in action: the concept was patented and proven, then later industrialized by firms with the capital to build the lines.
The caveat we attach: a research patent is a defensive and licensing asset, not a product. imec's grant evidences where the technique was proven; the commercialization, capacity, and economics belong to the foundries that adopted it.
For the period investor, the lesson is to watch the research layer. The features that define a leading node years later are often patented in consortia first — and a 2021-era backside-power grant is a clean example of that lead time.